Search

Drug Development in North America Novasep is Building Synthesis and Kilo Lab in US Facility

| Editor: Manja Wühr

CMO service supplier Novaseps is building a new synthesis laboratory and a kilo lab for its Standort Boothwyn (PA) facility. This will give North American companies range of specialized drug development technologies.

Related Companies

Andrew Brennan, general manager of Novasep’s US operations: “The new US laboratory greatly enhances Novasep’s global offering for CMO services.”
Andrew Brennan, general manager of Novasep’s US operations: “The new US laboratory greatly enhances Novasep’s global offering for CMO services.”
(Picture: Novasep )

Lyon/France – The establishment of synthesis and kilo lab will allow Novasep to offer both chemistry and purification services. It will enable the company to produce the initial kilogram scale batches of synthetic molecules that are needed for biological testing and preclinical trials.

This is a reaction to increasing demand from US customers for closer proximity to Novasep’s contract manufacturing services that accelerate early stage development and ease production scale-up. The new laboratory will start operations in May 2016. Novasep will equip the US facility with reactors up to 50L in size. The new laboratory will feature cryogenic capacities as well as standard chemistry. In terms of purification, it will provide North American customers with the complete portfolio of Novasep preparative chromatography processes, such as HPLC (Hipersep), SFC (Supersep) and state of the art evaporation. In addition, it will be equipped with all required analytical tools for PR&D (Process Research and Development), including process safety testing capabilities.

This article is protected by copyright. You want to use it for your own purpose? Contact us at support.vogel.de (ID: 43840682)